Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study.
Adverse effects
Biliary tract
Self-expandable metallic stents
Journal
Clinical endoscopy
ISSN: 2234-2400
Titre abrégé: Clin Endosc
Pays: Korea (South)
ID NLM: 101576886
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
17
05
2021
accepted:
11
07
2021
pubmed:
29
10
2021
medline:
29
10
2021
entrez:
28
10
2021
Statut:
ppublish
Résumé
Covered self-expandable metallic stents (CMSs) are widely used for malignant distal biliary obstructions (MDBOs) caused by pancreatic carcinoma. This study compared the efficacy and safety of the laser-cut-type and braided-type CMSs. To palliate MDBOs caused by pancreatic carcinoma, the laser-cut-type CMSs was used from April 2014 to March 2017, and the braided-type CMSs was used from April 2017 to March 2019. The tested self-expandable metallic stents were equipped with different anti-migration systems. In total, 47 patients received CMSs for MDBOs (24 laser-cut type, 23 braided-type). The time to recurrent biliary obstruction (TRBO) was significantly longer in the braided-type CMSs (p=0.0008), and the median time to stent dysfunction or patient death was 141 and 265 days in the laser-cut-type CMSs and braided-type CMSs, respectively (p=0.0023). Stent migration was the major cause of stent dysfunction in both groups, which occurred in 37.5% of the laser-cut-type CMSs and 13.0% of the braidedtype CMSs. There were no differences in the survival duration between the groups. The TRBO was significantly longer for the braided-type CMSs with an anti-migration system than for the laser-cuttype. Stent migration tended to be less frequent with the braided-type CMSs than with the laser-cut-type CMSs.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
Covered self-expandable metallic stents (CMSs) are widely used for malignant distal biliary obstructions (MDBOs) caused by pancreatic carcinoma. This study compared the efficacy and safety of the laser-cut-type and braided-type CMSs.
METHODS
METHODS
To palliate MDBOs caused by pancreatic carcinoma, the laser-cut-type CMSs was used from April 2014 to March 2017, and the braided-type CMSs was used from April 2017 to March 2019. The tested self-expandable metallic stents were equipped with different anti-migration systems.
RESULTS
RESULTS
In total, 47 patients received CMSs for MDBOs (24 laser-cut type, 23 braided-type). The time to recurrent biliary obstruction (TRBO) was significantly longer in the braided-type CMSs (p=0.0008), and the median time to stent dysfunction or patient death was 141 and 265 days in the laser-cut-type CMSs and braided-type CMSs, respectively (p=0.0023). Stent migration was the major cause of stent dysfunction in both groups, which occurred in 37.5% of the laser-cut-type CMSs and 13.0% of the braidedtype CMSs. There were no differences in the survival duration between the groups.
CONCLUSION
CONCLUSIONS
The TRBO was significantly longer for the braided-type CMSs with an anti-migration system than for the laser-cuttype. Stent migration tended to be less frequent with the braided-type CMSs than with the laser-cut-type CMSs.
Identifiants
pubmed: 34706489
pii: ce.2021.161
doi: 10.5946/ce.2021.161
pmc: PMC9178141
doi:
Types de publication
Journal Article
Langues
eng
Pagination
434-442Commentaires et corrections
Type : CommentIn
Références
Scand J Gastroenterol. 2015;50(12):1490-9
pubmed: 26133200
Radiology. 1996 Oct;201(1):167-72
pubmed: 8816539
Clin Gastroenterol Hepatol. 2006 Jun;4(6):790-6
pubmed: 16716757
J Gastroenterol. 2013 Nov;48(11):1293-9
pubmed: 23354624
Gastrointest Endosc. 2006 May;63(6):792-6
pubmed: 16650540
Dig Endosc. 2015 Jan;27(2):259-64
pubmed: 25209944
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Gut. 2004 May;53(5):729-34
pubmed: 15082593
Endoscopy. 2020 Aug;52(8):664-668
pubmed: 32316040
Am J Gastroenterol. 2013 Nov;108(11):1713-22
pubmed: 24042190
Dig Endosc. 2011 Oct;23(4):310-5
pubmed: 21951091
Endoscopy. 1989 Nov;21(6):280-2
pubmed: 2482170
Gastrointest Endosc. 2012 Jul;76(1):84-92
pubmed: 22482918
J Gastroenterol Hepatol. 2014 Sep;29(9):1744-9
pubmed: 24720610
Endoscopy. 2014 Nov;46(11):941-8
pubmed: 25321620
Gastrointest Endosc. 2010 Nov;72(5):907-14
pubmed: 21034891
Endoscopy. 1980 Jan;12(1):8-11
pubmed: 7353562
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Gastrointest Endosc. 2017 Jan;85(1):32-47
pubmed: 27546389
Surg Endosc. 2012 Jan;26(1):222-9
pubmed: 21858574
World J Gastroenterol. 2016 Aug 14;22(30):6917-24
pubmed: 27570427
Gastrointest Endosc. 2018 Aug;88(2):283-291.e3
pubmed: 29653120
Endoscopy. 1993 Mar;25(3):207-12
pubmed: 8519239
Gastrointest Endosc. 1988 Sep-Oct;34(5):412-7
pubmed: 2460394
J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):41-54
pubmed: 29032636
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Gastrointest Endosc. 2010 Nov;72(5):915-23
pubmed: 21034892
Gastrointest Endosc. 2009 Jul;70(1):37-44
pubmed: 19249766
Dig Dis Sci. 2018 Sep;63(9):2466-2473
pubmed: 29218484
Dig Endosc. 2021 May;33(4):648-655
pubmed: 32875614
Gut Liver. 2013 Nov;7(6):725-30
pubmed: 24312715
BMC Gastroenterol. 2017 Oct 11;17(1):105
pubmed: 29020933
Gut Liver. 2021 Jan 15;15(1):135-141
pubmed: 32340436
Gastrointest Endosc. 2009 Aug;70(2):317-21
pubmed: 19539920
Scand J Gastroenterol. 2013 Apr;48(4):459-65
pubmed: 23373541
Gut. 1982 May;23(5):371-5
pubmed: 7076014
Am J Surg. 1987 May;153(5):444-7
pubmed: 3578663
Endoscopy. 2011 Apr;43(4):317-24
pubmed: 21360423
Gut Liver. 2017 May 15;11(3):440-446
pubmed: 28208003
Gastrointest Endosc. 1998 Jan;47(1):1-7
pubmed: 9468416
Lancet. 1992 Dec 19-26;340(8834-8835):1488-92
pubmed: 1281903
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Gastrointest Endosc. 2011 Jan;73(1):64-70
pubmed: 21184871